(LIVN) LivaNova - Ratings and Ratios
Heart Pump, Neuromodulation, Cardiac Surgery
LIVN EPS (Earnings per Share)
LIVN Revenue
Description: LIVN LivaNova
LivaNova PLC is a healthcare company listed on NASDAQ under the ticker symbol LIVN, originating from the United Kingdom and operating within the Health Care Equipment sub-industry. The companys stock performance is a key area of focus for investors.
To evaluate LIVNs stock, its essential to examine its financial health and key performance indicators (KPIs). The Market Cap of $2.24B indicates a mid-cap stock with a considerable presence in the market. However, the negative Return on Equity (RoE) of -18.11% raises concerns about the companys profitability and ability to generate returns for shareholders.
The Forward P/E ratio of 20.66 suggests that investors are willing to pay a premium for expected future earnings growth. This could be driven by the companys potential for innovation and expansion in the healthcare equipment sector. Key economic drivers for LIVN include the demand for medical devices, technological advancements, and the overall healthcare expenditure in the regions they operate.
Investors should also consider the companys ability to manage its tax expenses effectively, as indicated by the yearly Income Tax Expense. A lower tax expense can contribute to higher net income, which is a crucial factor in determining the stocks attractiveness. Other relevant KPIs include revenue growth, operating margins, and cash flow generation, which can provide a more comprehensive understanding of LIVNs financial performance.
From a trading perspective, LIVNs stock has shown volatility, with an Average True Range (ATR) of 1.11, representing a 2.29% daily price movement. The stocks Beta of 0.925 indicates that it is slightly less volatile than the overall market. Analyzing the stocks moving averages, such as SMA20, SMA50, and SMA200, can help identify trends and potential buy or sell signals.
LIVN Stock Overview
| Market Cap in USD | 3,206m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1993-02-10 |
LIVN Stock Ratings
| Growth Rating | -15.1% |
| Fundamental | 51.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -9.79% |
| Analyst Rating | 4.09 of 5 |
LIVN Dividends
Currently no dividends paidLIVN Growth Ratios
| Growth Correlation 3m | 72.4% |
| Growth Correlation 12m | -25.5% |
| Growth Correlation 5y | -67.1% |
| CAGR 5y | 2.35% |
| CAGR/Max DD 3y | 0.05 |
| CAGR/Mean DD 3y | 0.14 |
| Sharpe Ratio 12m | 0.12 |
| Alpha | 0.00 |
| Beta | 0.959 |
| Volatility | 34.69% |
| Current Volume | 546.3k |
| Average Volume 20d | 561.5k |
| Stop Loss | 52.8 (-3.2%) |
| Signal | -0.64 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (-211.3m TTM) > 0 and > 6% of Revenue (6% = 78.6m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 2.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 18.26% (prev 61.48%; Δ -43.22pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 216.6m > Net Income -211.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (54.7m) change vs 12m ago 0.21% (target <= -2.0% for YES) |
| Gross Margin 69.07% (prev 68.03%; Δ 1.04pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.80% (prev 49.31%; Δ 3.48pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.17 (EBITDA TTM -73.2m / Interest Expense TTM 59.2m) >= 6 (WARN >= 3) |
Altman Z'' -2.13
| (A) 0.10 = (Total Current Assets 1.07b - Total Current Liabilities 827.1m) / Total Assets 2.51b |
| (B) -0.48 = Retained Earnings (Balance) -1.20b / Total Assets 2.51b |
| (C) -0.05 = EBIT TTM -128.6m / Avg Total Assets 2.48b |
| (D) -0.80 = Book Value of Equity -1.11b / Total Liabilities 1.38b |
| Total Rating: -2.13 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 51.62
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 5.33% = 2.66 |
| 3. FCF Margin 12.38% = 3.10 |
| 4. Debt/Equity 0.38 = 2.43 |
| 5. Debt/Ebitda -5.88 = -2.50 |
| 6. ROIC - WACC (= -15.91)% = -12.50 |
| 7. RoE -17.66% = -2.50 |
| 8. Rev. Trend 93.18% = 6.99 |
| 9. EPS Trend 68.93% = 3.45 |
What is the price of LIVN shares?
Over the past week, the price has changed by -3.52%, over one month by +2.37%, over three months by +22.95% and over the past year by +6.92%.
Is LivaNova a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LIVN is around 52.47 USD . This means that LIVN is currently overvalued and has a potential downside of -3.78%.
Is LIVN a buy, sell or hold?
- Strong Buy: 4
- Buy: 4
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LIVN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 65 | 19.2% |
| Analysts Target Price | 65 | 19.2% |
| ValueRay Target Price | 58.6 | 7.4% |
Last update: 2025-09-11 04:43
LIVN Fundamental Data Overview
CCE Cash And Equivalents = 593.6m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 14.3885
P/S = 2.4487
P/B = 2.8554
P/EG = 0.7055
Beta = 0.969
Revenue TTM = 1.31b USD
EBIT TTM = -128.6m USD
EBITDA TTM = -73.2m USD
Long Term Debt = 348.5m USD (from longTermDebt, last quarter)
Short Term Debt = 82.1m USD (from shortTermDebt, last quarter)
Debt = 430.6m USD (Calculated: Short Term 82.1m + Long Term 348.5m)
Net Debt = -120.2m USD (from netDebt column, last quarter)
Enterprise Value = 3.04b USD (3.21b + Debt 430.6m - CCE 593.6m)
Interest Coverage Ratio = -2.17 (Ebit TTM -128.6m / Interest Expense TTM 59.2m)
FCF Yield = 5.33% (FCF TTM 162.1m / Enterprise Value 3.04b)
FCF Margin = 12.38% (FCF TTM 162.1m / Revenue TTM 1.31b)
Net Margin = -16.14% (Net Income TTM -211.3m / Revenue TTM 1.31b)
Gross Margin = 69.07% ((Revenue TTM 1.31b - Cost of Revenue TTM 404.9m) / Revenue TTM)
Tobins Q-Ratio = -2.74 (set to none) (Enterprise Value 3.04b / Book Value Of Equity -1.11b)
Interest Expense / Debt = 2.85% (Interest Expense 12.3m / Debt 430.6m)
Taxrate = 28.38% (25.1m / 88.3m)
NOPAT = -128.6m (EBIT -128.6m, no tax applied on loss)
Current Ratio = 1.29 (Total Current Assets 1.07b / Total Current Liabilities 827.1m)
Debt / Equity = 0.38 (Debt 430.6m / last Quarter total Stockholder Equity 1.12b)
Debt / EBITDA = -5.88 (Net Debt -120.2m / EBITDA -73.2m)
Debt / FCF = 2.66 (Debt 430.6m / FCF TTM 162.1m)
Total Stockholder Equity = 1.20b (last 4 quarters mean)
RoA = -8.43% (Net Income -211.3m, Total Assets 2.51b )
RoE = -17.66% (Net Income TTM -211.3m / Total Stockholder Equity 1.20b)
RoCE = -8.32% (Ebit -128.6m / (Equity 1.20b + L.T.Debt 348.5m))
RoIC = -7.24% (NOPAT -128.6m / Invested Capital 1.78b)
WACC = 8.66% (E(3.21b)/V(3.64b) * Re(9.55%)) + (D(430.6m)/V(3.64b) * Rd(2.85%) * (1-Tc(0.28)))
Shares Correlation 3-Years: 84.85 | Cagr: 0.20%
Discount Rate = 9.55% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 71.16% ; FCFE base≈131.3m ; Y1≈118.9m ; Y5≈103.5m
Fair Price DCF = 26.54 (DCF Value 1.45b / Shares Outstanding 54.6m; 5y FCF grow -11.75% → 3.0% )
EPS Correlation: 68.93 | EPS CAGR: 24.09% | SUE: 1.56 | # QB: 2
Revenue Correlation: 93.18 | Revenue CAGR: 12.88% | SUE: N/A | # QB: None
Additional Sources for LIVN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle